David Morrison1, James Shaffer2, Gui-Shuang Ying2, Gil Binenbaum3. 1. Vanderbilt University Medical Center, Nashville Tennessee. Electronic address: david.morrison.1@vanderbilt.edu. 2. Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 3. Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
PURPOSE: To determine the prevalence of treatment-related ocular complications and disease progression following treatment for retinopathy of prematurity (ROP). METHODS: This was a retrospective cohort study of eyes treated for ROP at 29 North American neonatal intensive care units in the Postnatal Growth and ROP (G-ROP) Study. Data from the time of treatment through 15 months were abstracted from medical records by certified data collectors. Treatment-related complication (cataract, hyphema, glaucoma, corneal abrasion/opacity), and disease-progression (retinal fold, dragging, or stage 4 or 5 detachment) were calculated by treatment modality. Vitreous hemorrhage was classified separately, because it can relate to treatment or disease progression. RESULTS: Of 7,483 infants included in the study, 1,004 eyes (512 infants) underwent ROP treatment: 970 eyes received laser as initial therapy; 34 eyes received intravitreal bevacizumab (IVB). Median follow-up after treatment was 18 weeks. Overall, one or more complications occurred in 2.6% (95% CI, 1.8%-3.8%) laser treated eyes and no (0%; 95% CI, 0.0%-10.1%) IVB eyes. Disease-progression occurred in 9.2% (95% CI, 7.6%-11.2%) laser treated eyes, no (0%; 95% CI, 0.0-12.9%) IVB-only eyes. Vitreous hemorrhage occurred in 5.4% (95% CI: 4.1% - 7.0%) laser treated eyes, no IVB-only eyes. CONCLUSIONS: Rates of complications are very low following ROP treatment with either laser or IVB. Of laser-treated eyes, 9% experienced disease progression despite treatment.
PURPOSE: To determine the prevalence of treatment-related ocular complications and disease progression following treatment for retinopathy of prematurity (ROP). METHODS: This was a retrospective cohort study of eyes treated for ROP at 29 North American neonatal intensive care units in the Postnatal Growth and ROP (G-ROP) Study. Data from the time of treatment through 15 months were abstracted from medical records by certified data collectors. Treatment-related complication (cataract, hyphema, glaucoma, corneal abrasion/opacity), and disease-progression (retinal fold, dragging, or stage 4 or 5 detachment) were calculated by treatment modality. Vitreous hemorrhage was classified separately, because it can relate to treatment or disease progression. RESULTS: Of 7,483 infants included in the study, 1,004 eyes (512 infants) underwent ROP treatment: 970 eyes received laser as initial therapy; 34 eyes received intravitreal bevacizumab (IVB). Median follow-up after treatment was 18 weeks. Overall, one or more complications occurred in 2.6% (95% CI, 1.8%-3.8%) laser treated eyes and no (0%; 95% CI, 0.0%-10.1%) IVB eyes. Disease-progression occurred in 9.2% (95% CI, 7.6%-11.2%) laser treated eyes, no (0%; 95% CI, 0.0-12.9%) IVB-only eyes. Vitreous hemorrhage occurred in 5.4% (95% CI: 4.1% - 7.0%) laser treated eyes, no IVB-only eyes. CONCLUSIONS: Rates of complications are very low following ROP treatment with either laser or IVB. Of laser-treated eyes, 9% experienced disease progression despite treatment.
Authors: Brian A Darlow; Anna L Ells; Clare E Gilbert; Glen A Gole; Graham E Quinn Journal: Arch Dis Child Fetal Neonatal Ed Date: 2011-12-30 Impact factor: 5.747
Authors: G E Quinn; V Dobson; C C Barr; B R Davis; J T Flynn; E A Palmer; J Robertson; M T Trese Journal: Ophthalmology Date: 1991-01 Impact factor: 12.079
Authors: Domenico Lepore; Graham E Quinn; Fernando Molle; Antonio Baldascino; Lorenzo Orazi; Maria Sammartino; Velia Purcaro; Carmen Giannantonio; Patrizia Papacci; Costantino Romagnoli Journal: Ophthalmology Date: 2014-07-04 Impact factor: 12.079
Authors: Mrinali Patel Gupta; R V Paul Chan; Rachelle Anzures; Susan Ostmo; Karyn Jonas; Michael F Chiang Journal: Am J Ophthalmol Date: 2015-12-15 Impact factor: 5.258